AU Patent

AU2023201872B2 — Combinations of linagliptin and metformin

Assigned to Boehringer Ingelheim International GmbH · Expires 2025-03-06 · 1y expired

What this patent protects

COMBINATIONS OF LINAGLIPTIN AND METFORMIN The present invention relates to combinations of Linagliptin with metformin for use in the treatment of metabolic diseases in patients having chronic kidney disease (CKD).

USPTO Abstract

COMBINATIONS OF LINAGLIPTIN AND METFORMIN The present invention relates to combinations of Linagliptin with metformin for use in the treatment of metabolic diseases in patients having chronic kidney disease (CKD).

Drugs covered by this patent

Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim

Patent Metadata

Patent number: AU2023201872B2
Jurisdiction: AU
Classification: —
Expires: 2025-03-06
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.